In the News

For media inquiries, please contact cci@ccf.org

07/28/2022

New VR Platform Fuses Physical and Virtual Worlds in Parkinson’s Disease and Beyond

Recently scientists at Cleveland Clinic have developed a solution to the locomotion problem and have created a truly immersive VR experience. They are initiating research to use their platform to understand and better treat freezing of gait in patients with Parkinson’s disease (PD). Future research plans include use of the platform for early identification of PD and other neurodegenerative disorders in older adults.


07/25/2022

Prevent Biometrics Confirmed as Instrumented Mouthguard Provider for a Study During the 2022-23 Season

The RFU, Premiership Rugby and World Rugby confirm that Prevent Biometrics has been selected as the instrumented mouthguard (iMG) provider for a study with Premiership Rugby, Allianz Premier 15s and England representative teams for the 2022-23 season. A comprehensive procurement process took place to select the instrumented mouthguard provider for this study, which included a review of the validation work undertaken by the Rugby Football League in partnership with Leeds Beckett University in their pilot study for the TACKLE project.


07/22/2022

30 Great Chief Innovation Officers to Know | 2022

Chief innovation officers have become vital to digital transformation efforts and initiatives to keep health systems on the cutting edge of delivering patient care. Innovation chiefs are tasked with creating a culture of innovation across the system, accelerating research and development and managing venture capital funds. They also oversee efforts to harness the ingenuity and creativity of team members to improve operations and clinical care.


06/28/2022

Advanced NanoTherapies Announces Closing of Oversubscribed $7.2 Million Series A Financing

 Advanced NanoTherapies, Inc., a privately-held medical device company committed to solving vascular disease's most significant challenges through the creative applications of nanotechnology, today announced the closing of its oversubscribed $7.2 million Series A equity financing, marking a total of $12.5 million raised since September 2020. Funds will be used to complete the first-in-human clinical study in Australia of the SirPlux Duo drug-coated balloon (DCB) in de-novo coronary artery disease (CAD) lesions. Funding comes from various sources in the U.S., Canada, Europe, and Asia.


06/27/2022

GE Healthcare joins $33M funding for Cleveland Clinic spinout Centerline Biomedical

With FDA clearance for its flagship product secured and a U.S. launch under way, Centerline Biomedical’s current focus is twofold: bringing its surgical navigation technology into more operating rooms around the world and expanding its indications into a broader range of surgical procedures.

The task of juggling that dual focus just got somewhat smoother, as Centerline announced on Monday the close of a series B equity financing that’ll bolster all of its ongoing endeavors.


06/23/2022

Astrotech Subsidiary and Cleveland Clinic Expand Breath Analysis Study to Detect Multiple Diseases

Astrotech Corporation’s (NASDAQ: ASTC) subsidiary, BreathTech Corporation, announced today that it has amended its Joint Development and Option Agreement with Cleveland Clinic to include additional areas of focus. Under the amended agreement, ongoing work around development of a rapid breath test for COVID-19 will be expanded to utilize BreathTech’s core mass spectrometry technology to screen for a variety of diseases spanning the entire body. The project will focus on detecting bloodstream infections, respiratory infections such as influenza types A and B and respiratory syncytial virus (RSV), carriage of Staphylococcus aureus, and Clostridioides difficile (C. diff) infections.


05/19/2022

Cardionomic Announces First Patient Enrolled in STIM-ADHF Study

Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce initial enrollment in their STIM-ADHF Study. The study will evaluate therapy optimization and system management of the Cardiac Pulmonary Nerve Stimulation (CPNS™) System in patients suffering from Acute Decompensated Heart Failure (ADHF), defined as new or worsening symptoms of heart failure. The first patient was enrolled by Martin Hudec, MD., PhD., Principal Investigator at SUSCCH, Banská Bystrica, Slovakia. Up to fifty patients are expected to be enrolled worldwide.


05/19/2022

Centerline Biomedical Announces Successful Structural Heart Animal Study

Centerline Biomedical, Inc. (Centerline) announced Thursday the completion of the second in a series of structural heart navigation animal studies. Physicians from Cleveland Clinic's top-ranked Heart, Vascular and Thoracic Institute evaluated the feasibility of applying the company's augmented reality image guidance technology to navigate structures in a beating heart. Structural heart disease is a multi-billion-dollar market and one of the fastest growing segments within healthcare.


05/12/2022

Centerline Biomedical Launches Research and Development Collaboration with Air Force

Centerline Biomedical, Inc. (Centerline) announced Thursday that the Cleveland-based startup company has launched work on a contract to apply its IOPS™ technology platform to service the needs of its collaborators at the 59th Medical Wing (59 MDW), the Air Force's premier healthcare, medical education and research, and readiness wing, located at Joint Base San Antonio-Lackland.


05/11/2022

Cleveland Diagnostics Announces Inclusion of IsoPSA® in National Comprehensive Cancer Network® Guidelines for Prostate Cancer Early Detection

CLEVELAND--()--Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer Early Detection (version 1.2022). The NCCN panel now recommends the use of IsoPSA as an option to further define the probability of high-grade prostate cancer (Gleason score ≥ 3+4, Grade Group 2 or higher) prior to a first biopsy or after a negative biopsy.


   < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >   

Get In Touch With Us